文献速递肝病消化道肿瘤与早癌

HIV/HCV合并感染肝硬化患者与HCV单独感染患者相比不再具有更高的肝细胞癌或终末期肝病风险

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
PubMed 文献 · Hepatology · 2019-03-15

在法国两项前瞻性全国队列中,比较1253例HCV单独感染与175例HIV/HCV合并感染的代偿期肝硬化患者,年龄校正后两组5年肝细胞癌和肝功能失代偿累积发生率相似,但HIV/HCV合并感染组总体死亡率更高(SHR=1.88)。

要点

  • 年龄校正后,HIV/HCV合并感染与HCV单独感染肝硬化患者的5年肝细胞癌和肝功能失代偿累积发生率相似。
  • HIV/HCV合并感染组年龄校正后总体死亡率高于HCV单独感染组(SHR=1.88;95%CI 1.15-3.06;P=0.011)。
  • 肝硬化的严重程度、年龄和未获得持续病毒学应答与肝功能失代偿及肝细胞癌相关,而非HIV状态。

核心结论

  • 在HCV感染肝硬化患者中,HIV合并感染不再与更高的肝细胞癌和肝功能失代偿风险相关,但死亡率增加持续存在,归因于肝外情况。

研究设计与样本

  • 研究纳入法国两项前瞻性全国队列(ANRS CO12 CirVir和CO13 HEPAVIH)中的1253例HCV单独感染和175例HIV/HCV合并感染肝硬化患者,肝硬化均为代偿期(Child-Pugh A)、无既往并发症史且经肝活检评估。

主要发现

  • 基线时HIV/HCV合并感染患者更年轻(47.5岁 vs 56.0岁;P<0.001),男性比例更高(77.1% vs 62.3%;P<0.001),基线和随访结束时HCV清除率与HCV单独感染患者相似。
  • 80.4%的HIV/HCV合并感染患者HIV病毒载量检测不到。
  • 年龄校正后,HIV/HCV合并感染组与HCV单独感染组的5年肝细胞癌累积发生率分别为8.5%和13.2%(P=0.12),肝功能失代偿累积发生率分别为12.8%和15.6%(P=0.40)。
  • 年龄校正后总体死亡率在HIV/HCV合并感染组更高(SHR=1.88;95%CI 1.15-3.06;P=0.011)。
  • 与肝功能失代偿和肝细胞癌相关的因素为年龄、未获得持续病毒学应答和肝硬化严重程度,而非HIV状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease. However, owing to better efficacy and safety of combination antiretroviral therapy (cART), and increased access to HCV therapy, whether this condition remains true is still unknown. Overall, 1,253 HCV mono-infected patients and 175 HIV/HCV co-infected patients with cirrhosis, included in two prospective French national cohorts (ANRS CO12 CirVir and CO13 HEPAVIH), were studied. Cirrhosis was compensated (Child-Pugh A), without past history of complication, and assessed on liver biopsy. Incidences of liver decompensation (LD), hepatocellular carcinoma (HCC), and death according to HIV status were calculated by a Fine-Gray model adjusted for age. Propensity score matching was also performed to minimize confounding by baseline characteristics. At baseline, HIV/HCV patients were younger (47.5 vs. 56.0 years; P < 0.001), more frequently males (77.1% vs. 62.3%; P < 0.001), and had at baseline and at end of follow-up similar rates of HCV eradication than HCV mono-infected patients. A total of 80.4% of HIV/HCV patients had an undetectable HIV viral load. After adjustment for age, 5-year cumulative incidences of HCC and decompensation were similar in HIV/HCV and HCV patients (8.5% vs. 13.2%, P = 0.12 and 12.8% vs. 15.6%, P = 0.40, respectively). Overall mortality adjusted for age was higher in HIV/HCV co-infected patients (subhazard ratio [SHR] = 1.88; 95% confidence interval [CI], 1.15-3.06; P = 0.011). Factors associated with LD and HCC were age, absence of sustained virological response, and severity of cirrhosis, but not HIV status. Using a propensity score matching 95 patients of each group according to baseline features, similar results were observed. Conclusion: In HCV-infected patients with cirrhosis, HIV co-infection was no longer associated with higher risks of HCC and hepatic decompensation. Increased mortality, however, persisted, attributed to extrahepatic conditions.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Salmon-Ceron D, Nahon P, Layese R, et al. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. Hepatology. 2019. PMID: 30569448. doi:10.1002/hep.30400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。